会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Heterodimer complex of RXR and NURR1 or NGFI-B
    • RXR和NURR1或NGFI-B的异二聚体复合物
    • US06458926B1
    • 2002-10-01
    • US08877966
    • 1997-06-18
    • Ronald M. EvansBarry M. FormanKazuhiko Umesono
    • Ronald M. EvansBarry M. FormanKazuhiko Umesono
    • C07K14435
    • C07K14/70567C07K2319/00G01N33/6875G01N33/74
    • Heterodimerization is a common paradigm among eucaryotic transcription factors, though it remains unclear how individual monomers contribute to the overall transcriptional activities of the complex. The 9-cis retinoic acid receptor (RXR) serves as a common heterodimerization partner for several nuclear receptors including the thyroid hormone (T3R), retinoic acid (RAR) and vitamin D receptors. A strategy has been devised to examine the transcriptional properties of each receptor individually or when tethered to a heterodimeric partner. It has been found that the intrinsic activity of RXR is masked in RXR-T3R and RXR-RAR heterodimers. In contrast, a novel RXR-Nurr1 heterodimer described herein is highly responsive to RXR ligands, suggesting that different partners exert unique allosteric control over the RXR response. These findings establish a novel 9-cis retinoic acid response pathway and resolve the paradox as to how T3R, RAR and VDR contribute to distinct physiologic pathways while sharing a common RXR subunit.
    • 异源二聚化是真核转录因子中的常见范例,尽管单个单体如何有助于复合物的整体转录活性仍不清楚。 9-顺式视黄酸受体(RXR)用作几种核受体(包括甲状腺激素(T3R),视黄酸(RAR)和维生素D受体)的常见异源二聚体配偶体。 已经设计出一种策略来单独检测每个受体的转录特性,或者当连接到异二聚体配偶体时。 已经发现在RXR-T3R和RXR-RAR异二聚体中RXR的固有活性被掩蔽。 相比之下,本文描述的新型RXR-Nurr1异源二聚体对RXR配体具有高度响应性,表明不同的合作伙伴对RXR应答发挥独特的变构控制。 这些研究结果建立了一种新的9-顺式视黄酸反应途径,并解决了T3R,RAR和VDR如何在共享一个共同的RXR亚基时对不同的生理途径有贡献的矛盾。
    • 6. 发明授权
    • Retinoic acid receptor composition
    • 视黄酸受体组成
    • US5274077A
    • 1993-12-28
    • US975777
    • 1992-11-13
    • Ronald M. EvansEstelita S. OngPrudimar S. SeguiCatherine C. ThompsonKazuhiko UmesonoVincent Giguere
    • Ronald M. EvansEstelita S. OngPrudimar S. SeguiCatherine C. ThompsonKazuhiko UmesonoVincent Giguere
    • C07K14/705C12N15/12C12Q1/68C07K13/00
    • C07K14/70567C12Q1/6897C07K2319/61C07K2319/715C07K2319/81
    • A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by CDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand--(e.g., glucocorticoid) inducible promoter is dependent on the presence of the new ligand. The novel method is illustrated in part by showing that the ligand for the new receptor protein is the retinoid, retinoic acid.
    • 公开了一种新型视黄酸受体。 新型受体由携带在质粒phRAR1上的CDNA编码,其已经用美国典型培养物保藏中心专利保藏。 还公开了嵌合受体蛋白。 通过在糖皮质激素,盐皮质激素,雌激素相关,甲状腺和视黄酸受体之间交换功能结构来构建嵌合体。 另外,公开了用于鉴定受体蛋白质的功能性配体的新方法。 利用激素受体的模块化结构的方法和功能域可以互换的想法将已知受体的DNA结合结构域(例如糖皮质激素)替代推定的新受体的DNA结合结构域 受体。 当在细胞中表达时,产生的嵌合构型产生杂合受体,其配体(例如,糖皮质激素)诱导型启动子的活化取决于新配体的存在。 该新方法部分地通过显示新受体蛋白质的配体是类视黄醇,视黄酸来说明。